A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson’s disease symptoms in a small, mid-stage trial funded by the French Ministry of Health.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Accept